Wednesday, April 24, 2024
News

Study finds cellular exosomes could improve the delivery of anticancer drugs to tumours

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Glasgow | April 20, 2022 8:24:50 PM IST
According to a new study, exosomes, or small bubbles that transport molecules from one cell to another, can be effective vehicles for delivering cancer treatments to tumours.

The findings of the study were published in the journal, 'Cancer Medicine'.

The study was led by researchers from the University of Glasgow, Griffith University, and Yale University.

In the study, researchers used exosomes produced by cells called adipose-derived mesenchymal stem cells (ADSCs) to deliver an RNA-based anti-cancer treatment (miR-138-5p) to bladder cancer tumours in mice.

"The present results reveal that ADSC-derived exosomes are an effective delivery vehicle for small molecule drugs in vivo, and exosome-delivered miR-138-5p is a promising therapeutic agent for bladder cancer treatment," the authors wrote. (ANI)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE SCIENCE NEWS
Study reveals positive effect of midazol...
Study finds how liver inflammation assoc...
Study reveals novel therapeutic target f...
Study finds common complication of atria...
Researchers discover how complexities in...
Study finds how adding chemotherapy to h...
More...
 
INDIA WORLD ASIA
'It makes clear Congress' mindset': BJP'...
'Congress has decided to destroy India':...
'We are waiting to welcome him.': BJD's ...
Fire breaks out at plastic godown in And...
'He can't digest a common labourer becom...
'Redistribution of wealth in interest of...
More...    
 
 Top Stories
Indian Army conducts training for 1... 
Shameik Moore, Paris Jackson to lea... 
Bigg Boss 13 reunion: Rashami Desai... 
"Pitroda has done an x-RAY of Congr... 
WB teachers' recruitment case: stat... 
"Grateful to PM Modi for the way he... 
Kim Kardashian wants Taylor Swift t... 
Apple slashes Vision Pro production...